AAN 2025 | A comparative analysis of DOACs and VKAs for the treatment of cerebral venous sinus thrombosis

So in our research we aim to perform a comparative analysis of direct oral anticoagulants and vitamin K antagonists for treating cerebral venous sinus thrombosis. So cerebral venous sinus thrombosis is a rare type of stroke that occurs in the dural veins. So these kind of patients had to be treated with anticoagulation, right? So there’s no substantial research supporting the use of any of them, either direct oral anticoagulants or vitamin K antagonists. So our work aimed to fill this gap in the body of evidence by proving that one of them is better than the other, okay? So we directly compared these two agents through a systematic review and meta-analysis. Then we performed a systematic review and we included a total of 10 studies, being six RCTs and four observational studies with over 2,000 patients. So we performed many outcomes like partial re-canalization, complete re-canalization, and any recanalization and we found no differences between groups for these outcomes. So we also assessed the modified Rankin scale 0 to 2 and 3 to 5 and we also did not find any differences between groups. So in conclusion our meta-analysis found no differences between groups of patients with cerebral venous sinus thrombosis treated with DOAC or VKA. In conclusion, our study supports that both intervention and control may have similar benefits for these kind of patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.